# Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer

> **NCT00841113** · PHASE3 · COMPLETED · sponsor: **Speciality European Pharma Limited** · enrollment: 177 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Abarelix
- **DRUG:** Goserelin plus Bicalutamide

## Key facts

- **NCT ID:** NCT00841113
- **Lead sponsor:** Speciality European Pharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-01
- **Primary completion:** 2001-02
- **Final completion:** 2003-02
- **Target enrollment:** 177 (ACTUAL)
- **Last updated:** 2009-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00841113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00841113, "Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00841113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*